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Cancer therapyNuclear factor-erythroid 2 p45-related factor 2 (NRF2, also known asNfe2l2) plays a critical role in regulating cel-
lular defense against electrophilic and oxidative stress by activating the expression of an array of antioxidant re-
sponse element-dependent genes. On one hand, NRF2 activators have been used in clinical trials for cancer
prevention and the treatment of diseases associatedwith oxidative stress; on the other hand, constitutive activa-
tion of NRF2 inmany types of tumors contributes to the survival and growth of cancer cells, as well as resistance
to anticancer therapy. In this review, we provide an overview of the NRF2 signaling pathway and discuss its role
in carcinogenesis.We also introduce the inhibition of NRF2 by nuclear receptors. Further, we address the biolog-
ical signiﬁcance of regulation of the NRF2 signaling pathway by nuclear receptors in health and disease. Finally,
we discuss the possible impact of NRF2 inhibition by nuclear receptors on cancer therapy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
In general, people are exposed to a wide variety of environmental
pollutants and toxicants that generate oxidative stress in cells. Such
stress elevates the generation of reactive oxygen species (ROS) that
cause DNA damage such as base modiﬁcation (modiﬁcation of guanine,
causing G→ T transversions), rearrangement of the DNA sequence,
single-strand breaks, and mutations in tumor-suppressor genes that
ultimately lead to the initiation, promotion, and progression of cancer
[1,2]. ROS are oxygen by-products from exogenous and endogenous
sources. Numerous studies suggest that oxidative stress in cells causes
not only cancer but also other chronic diseases such as diabetes,1C2; ARE, antioxidant response
CNC homologue 1; BBN, (N-
a 2; Bcl-xL, B-cell lymphoma—
in; CBP, CREB binding protein;
domain; Dex, dexamethasone;
r alpha; ERRβ, estrogen-related
lutathione; GST, glutathione S-
miRNA, microRNA; Neh, NRF2–
se 1; NRF2, NF-E2 p45-related
r; ROS, reactive oxygen species;
ha; SMRT, silencing mediator of
ucleotide polymorphism; TXS,
ehydrogenase type 1
: +86 571 88208266.
entang@zju.edu.cn (X. Tang).arthritis, asthma, chronic obstructive pulmonary disease, and neurode-
generative diseases [3]. Nuclear factor erythroid 2-related factor 2
(NRF2) is a transcription factor which belongs to the Cap ‘N’ Collar fam-
ily that contains a highly-conserved basic leucine zipper structure [4].
Under oxidative stress, NRF2 regulates the series of genes known as an-
tioxidant response elements (AREs) or electrophile response elements.
ARE and/or electrophile response element genes express various anti-
oxidants and phase-II cytoprotective and detoxifying enzymes such as
glutathione S-transferases (GSTs), NAD(P)H:quinone oxidoreductase
(NQO1), aldo-keto reductase, and heme oxygenase-1. These enzymes
are responsible for the detoxiﬁcation and neutralization of xenobiotics
and ROS, and so protect against the diseases associated with oxidative
stress [5,6]. In addition, it has also been shown that NRF2 not only reg-
ulates cytoprotective gene expression but also cell proliferation [7].
2. KEAP1–NRF2–ARE signaling pathway
2.1. KEAP1 (Kelch-like ECH-associated protein 1)
KEAP1 is a 69-kD, cysteine-rich protein (27 cysteine residues), a sub-
strate adaptor for cullin(Cul3)-containing E3 ubiquitin ligase. KEAP1
contains ﬁve domains (Fig. 1A): an N-terminal region, a BTB dimeriza-
tion domain (Broad-Complex, Tramtrack, and Bric a′ brac), a cysteine-
rich intervening region (IVR domain), a Kelch domain/double glycine
repeat (DGR) domain possessing 6 Kelch repeats, and a C-terminal re-
gion [8]. The BTB domain is crucial for KEAP1 homodimerization and in-
teraction with the Cul3-based ubiquitin E3 ligase complex for NRF2
ubiquitination [9,10]. A Cys151 residue in the BTB domain plays an
Fig. 1. Domain structures of KEAP1 and NRF2. (A) KEAP1 has ﬁve domains: (1) the N-terminal domain, (2) a BTB domain responsible for KEAP1 homodimerization and association with
Cul3, (3) IVR, a cysteine-rich domain that acts as a sensor for NRF2 inducers, (4) the Kelch/DGR domain that is important for bindingwith theNeh2 domain ofNRF2, and (5) the C-terminal
domain. (B) NRF2 contains seven domains known as Neh1–Neh7. The N-terminal domain Neh2 contains two motifs, DLG and ETGE, which are responsible for binding KEAP1. The Neh3,
Neh4, and Neh5 domains are important for the transactivation activity of NRF2. The Neh7 domain binds RXRα and inhibits ARE gene activity. Neh6 is a serine-rich domain required for β-
TrCP binding. The C-terminal domain, Neh1, is a leucine zipper motif responsible for DNA-binding and dimerization with Maf.
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the BACK domain) is sensitive to oxidation and has critical, highly-
reactive cysteine residues such as Cys273, Cys288, and Cys297, that
act as sensors for NRF2 inducers [12]. Moreover, Cys288 and Cys297
are critical for the repression of NRF2 activity [13]. The DGR domain
contains six repetitive Kelch structures that speciﬁcally bind to the con-
served N-terminal Neh2 domain of NRF2 and negatively regulate its ac-
tivity [14]. In addition, Niture et al. showed that the DGR domain of
KEAP1 binds with the BH2 domain of Bcl-2 (B-cell lymphoma 2) and
targets the Cul3-Rbx1-mediated degradation of Bcl-2 [15]. The DGR
and C-terminal region domains are collectively named the DC domain.
The BTB-DC domains together play a crucial role in NRF2 proteasomal
degradation and repression.
2.2. NRF2
NRF2, the key activator of the pathway, has seven functional
domains: Neh1–Neh7 (NRF2–ECH homology) (Fig. 1B). Neh1 contains
a basic leucine zipper motif that heterodimerizes with small musculo-
aponeurotic ﬁbrosarcoma protein, DNA, and other transcription part-
ners [16]. Plafker et al. have shown that the Neh1 domain binds with
ubiquitin-conjugating enzyme to regulate the stability and enhance
the transcriptional activity of NRF2 [17]. Neh2, the N-terminal domain,
contains twomotifs known as DLG and ETGE. Thesemotifs are essential
for the interaction between NRF2 and the Kelch domains of KEAP1, the
stability of NRF2, and NRF2 ubiquitination. However, the DLGmotif has
less afﬁnity for Kelchdomains than the ETGEmotif [18,19]. The carboxy-
terminal Neh3 domain interacts with the transcription co-activator
known as CHD6 (a chromo-ATPase/helicase DNA-binding protein),
which is critical for the transactivation of ARE-dependent genes [20].
The Neh4 and Neh5 domains bind with the CH3 domains of another
transcriptional co-activator, CBP (CREB-binding protein), which medi-
ates the transactivation of NRF2 target genes [21]. In addition, a recent
study has shown that these two transactivation domains interact with
the nuclear cofactor RAC3/AIB1/SRC-3 and enhance NRF2-targeted
ARE gene expression [22]. Speciﬁcally, Neh5 has a redox-sensitive
nuclear-export signal that regulates the cellular localization of NRF2
[23]. Neh6 is a serine-rich domain containing two motifs (DSGIS andDSAPGS) that interact with β-transducin repeat-containing protein
(β-TrCP) that acts as a substrate receptor for the Skp1–Cul1–Rbx1/
Roc1 ubiquitin ligase complex. These two distinct β-TrCP recognition
motifs of the Neh6 domain are important to control the stability of
NRF2 with regard to glycogen synthase kinase-3-targeted SCF/β-TrCP-
dependent degradation. It is noteworthy that Neh6 controls the stability
of NRF2 in a KEAP1-independent manner [24–26]. Recently, we discov-
ered a seventh domain that we named Neh7. Neh7 speciﬁcally interacts
with retinoic X receptor alpha (RXRα), a nuclear receptor that inhibits
the NRF2–ARE signaling pathway [27].
2.3. Regulation of NRF2 by KEAP1
Under basal homeostatic conditions, NRF2 is tethered in the cyto-
plasm by the actin-bound protein KEAP1, also known as INRF2 (inhibi-
tor of NRF2) [8,28] (Fig. 2). KEAP1 is a redox-regulated substrate
adaptor protein for a Cul3-dependent ubiquitin ligase complex that
targets NRF2 for ubiquitylation and subsequent proteasomal degrada-
tion. The highly-reactive cysteine residues in KEAP1 are involved in
the degradation and the stabilization of NRF2 [29].
Oxidative stress and NRF2 inducers activate NRF2 in cells where it
escapes from KEAP1 retention, which leads to enhanced accumula-
tion of NRF2. Thereby, NRF2 translocates into the nucleus where it
heterodimerizes with small Maf proteins and transactivates ARE-
driven gene expression [30] (Fig. 2). It is important to note that small
Maf proteins such as MafF, MafG, and MafK belong to the basic leucine
zipper transcription factor family, which plays a crucial role inmamma-
lian gene regulation [31]. Small Maf proteins form heterodimers with
members of the CNC transcription factors that bind with ARE, and also
form homodimers that bind with speciﬁc DNA motifs known as Maf-
recognition elements, both acting as transcriptional regulators [32,33].
It has been suggested that NRF2–MafG heterodimerization causes the
masking of a nuclear export signal in the NRF2 basic leucine zipper do-
main that leads to the enhanced retention of NRF2 proteins in the nucle-
us [34].
The exact molecular mechanism of NRF2 activation by thiol modiﬁ-
cation remains in question. However, several lines of evidence suggest
that the NRF2 inducers form an intermolecular disulﬁde bond between
Fig. 2. The KEAP1–NRF2–ARE pathway. In the basal state, NRF2 binds to KEAP1 at its two motifs (ETGE and DLG). KEAP1 ubiquitinates NRF2 and this is followed by proteasomal degra-
dation. In the induced state, NRF2 is protected from KEAP1 repression and translocates into the nucleus. In the nucleus, NRF2 binds to smallMaf proteins through the Neh 1 domainwhich
is responsible for the transactivation of ARE gene expression.
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the KEAP1 dimer. Therefore, formation of the disulﬁde bond causes the
DGR domains in dimeric KEAP1 to separate, leading to the stabilization
of NRF2 [13]. Moreover, the NRF2 inducer sulforaphane predominantly
causes a conformational change in KEAP1 by forming a thionoacyl ad-
duct in the Kelch domain, rather than in the central linker domain, lead-
ing to NRF2 stabilization [35]. Similarly, Fourquet et al. showed that
exposure toH2O2 andnitrosative agents promotes the formation of a di-
sulﬁde link between two KEAP1molecules through the reactive Cys151
residue that leads to the liberation of NRF2 from the KEAP1 dimer [36].
Interestingly, Bensasson et al. showed that diphenols induce NQO1
expression via a two-step process: (i) oxidation of diphenol inducers
to their quinone derivatives, and (ii) oxidation of highly-reactive thiols
of the protein sensor KEAP1 by quinones [37]. Another line of evidence
shows that KEAP1 interacts with NRF2 through a “hinge and latch”
mechanism in which the DLG and ETGE motifs of NRF2 bind with the
KEAP1 homodimer; since the ETGE motif has a higher afﬁnity than the
DLG motif for KEAP1, ETGE acts as a hinge and DLG acts as a latch.
NRF2 ﬁrst binds with KEAP1 through the hinge, then by the latch. Oxi-
dative or electrophilic insults disrupt one or both motifs of NRF2 from
KEAP1, which leads to dissociation of NRF2 from KEAP1. As a result, de
novo synthesized NRF2 accumulates in the cell and this is followed by
nuclear translocation and ARE gene expression [38].
From a different perspective, phosphorylation of NRF2 by a series of
protein kinases can also lead to changes in the NRF2–KEAP1 complex
and subsequent stabilization of NRF2. This was ﬁrst shown in HepG2
cells using a reporter gene assay where protein kinase C provokes the
phosphorylation of NRF2, which directs the dissociation of NRF2 from
KEAP1 and promotes the nuclear localization of NRF2 [39]. Similarly,
protein kinases such as c-jun N-terminal kinase, extracellular signal-
regulated kinase, casein kinase 2, and phosphorylate NRF2, and this
leads to the liberation of NRF2 from KEAP1 resulting in overexpres-
sion of NRF2 [40–42]. In contrast to the above, several studies havedemonstrated that proteins such as p21, p62, WTX tumor suppressor
protein, partner and localizer of BRCA2, and DPP3 also promote the dis-
sociation of NRF2 from KEAP1 [43–50].
Interestingly, recent studies have revealed thatmicroRNAs (miRNAs)
play a major role in the activation and/or inhibition of NRF2-mediated
ARE signaling. miRNAs are a class of small non-coding RNA molecules,
18–25 nucleotides in length, that regulate the post-transcriptional ac-
tivity of many genes [51]. For the ﬁrst time, Sangokoya et al. explained
the interaction between NRF2 and miRNAs in patients with homozy-
gous sickle-cell disease. They revealed that the miR-144 directly re-
presses NRF2 activity in the K562 cell-line and primary erythroid
progenitor cells [52]. Similarly, miR-28 targets the 3′ untranslated re-
gion (3′-UTR) of NRF2 mRNA and decreases NRF2-targeted gene ex-
pression in a KEAP1-independent manner in breast epithelial cells
[53]. However, Eadeset al. showed that miR-200a activates NRF2 in a
KEAP1-dependent manner in breast cancer cells; miR-200a targets the
3′UTR of KEAP1 and that leads to the degradation of KEAP1 mRNA
[54]. Moreover, Chorley et al. provided ChIP sequencing data which re-
vealed that a wide variety of miRNAs could interact with NRF2 and reg-
ulate its transcription. However, more individual experimental data are
required to conﬁrm those miRNAs that interact with NRF2 [55]. More
recently, Singh et al. showed that NRF2 in turn can also regulate the ex-
pression of miRNAs. They found that pentose phosphate pathway (PPP)
activity is modulated bymiR-1 and miR-206, and NRF2 upregulates the
expression of PPP enzymes by increasing the expression of these two
miRNA species [56]. However, little is known about NRF2 regulation
of these miRNAs.
3. Dual role of NRF2 in carcinogenesis
Several studies on the NRF2–ARE pathway revealed that NRF2 plays
a crucial role in cancer chemoprevention and tumor suppression in nor-
mal cells. From a different perspective, NRF2 is also considered to play a
1878 A. Namani et al. / Biochimica et Biophysica Acta 1843 (2014) 1875–1885major role in tumorigenesis and tumor protection. These two paradox-
ical roles have been referred as the ‘dual role of NRF2’.
3.1. Chemopreventive and tumor-suppressive role of NRF2
Evidence of the chemopreventive role of NRF2 is well-documented.
Initially, it was shown that overexpression of NRF2 positively regulates
the ARE of the human NQO1 gene in human hepatoblastoma and mon-
key kidney cells [57]. Further studies using NRF2-deﬁcient mice have
shown the critical role of NRF2 in chemoprevention; the degree of GST
andNQO1 gene-induction in NRF2-deﬁcient homozygousmice is signif-
icantly lower than in NRF2-heterozygous mice [16]. Similarly, NRF2-
deﬁcientmice showa signiﬁcantly increased burden of gastric neoplasia
after treatmentwith a carcinogen such as benzo[a]pyrene than dowild-
type mice. In addition, NRF2-knockout mice have lower hepatic and
gastric activity of GST andNQO1 thanwild-typemice [58]. Furthermore,
the incidence of BBN (N-nitrosobutyl(4-hydroxybutyl)amine)-induced
urinary bladder carcinoma is signiﬁcantly higher in NRF2 knockout
than in wild-type mice. In addition, the chemopreventive efﬁcacy of
oltipraz against urinary bladder carcinogenesis and BBN detoxiﬁcation
is mediated by the NRF2–ARE pathway [59]. Similarly, NRF2-knockout
mice are susceptible to 7,12-dimethylbenz(a)anthracene-induced skin
tumorigenesis. The chemopreventive effects of sulforaphane against
the carcinogens 7,12-dimethylbenz(a)anthracite or 12-O-tetradeca-
noylphorbol-13-acetate in skin tumors are mediated through NRF2.
Moreover, sulforaphane signiﬁcantly inhibits skin tumorigenesis in
wild-type but not NRF2-null mice [60]. It is noteworthy that, in wild-
type mice, the speciﬁc hepatic activity of GST and NQO1 is increased by
the chemoprotective agent 3H-1, 2-dithiole-3-thione but not in NRF2-
knockout mice [61]. Besides, NRF2-null mice show accelerated DNA
adduct formation in lung tumors after exposure to diesel exhaust [62].
Further evidence supports the hypothesis that NRF2-deﬁciency in lung
cancer cells creates a microenvironment that facilitates metastasis [63].
Indeed, numerous studies have demonstrated that natural cancer-
chemopreventive compounds induce phase-II detoxiﬁcation enzymes
through a mechanism dependent on NRF2–ARE signaling (see the re-
cent review by Magesh et al. [64] for further information on NRF2 acti-
vators). In addition, based on a wide variety of studies, several natural
and synthetic NRF2 inducers such as isothiocyanates (sulforaphane),
curcumin, and dithiolethiones (oltipraz) have been tested in clinical tri-
als for chemoprevention in different cancers [65–67].
3.2. Oncogenic and tumor-protective role of NRF2
Surprisingly, a number of studies have demonstrated that NRF2
protects tumor cells and promotes oncogenesis. These roles have been
referred to as the ‘dark side of NRF2’ [68].Wang et al. showed that stable
overexpression of NRF2 results in enhanced resistance of cancer cells to
chemotherapeutic agents such as cisplatin, doxorubicin, and etoposide.
Transient transfection of NRF2-small interfering RNA renders cancer
cells more susceptible to these drugs. Upregulation of NRF2 by tert-
butylhydroquinone also enhances the resistance of cancer cells [68].
Singh et al. showed that NRF2 enhances the expression of drug-efﬂux
pumps (such as ATP-binding cassette, subfamily G, member 2), which
in turn facilitates the chemoresistance and tumorigenicity of lung can-
cer cells [69]. Further experiments showed that oncogenes such as K-
Ras, B-Raf, and Myc increase the transactivation of NRF2 that reduces
the endogenous ROS level, which leads to the promotion of tumorigen-
esis [70,71]. Recently, Mitsuishi et al. showed that NRF2 redirects
glucose and glutamine into anabolic pathways, and this enables NRF2
to enhance metabolic activity and growth, facilitating tumor-cell prolif-
eration [72]. Interestingly, NRF2 upregulates the transcription of anti-
apoptotic proteins such as Bcl-2 and Bcl-xL, leading to decreased
apoptosis, enhanced survival, and drug resistance in cancer cells [73,74].
In contrast, RNA-interference-mediated silencing of NRF2 expres-
sion in non-small-cell lung cancer A549 cells and prostate cancer cellsshows that NRF2 increases the sensitivity to chemotherapeutic drugs
and confers radiosensitivity [75–77]. Moreover, constitutive activation
of NRF2 protects cancer cells against ionizing radiation and provokes
radioresistance in non-small-cell lung cancer cells [78].
Somatic mutations in NRF2 also play a major role in tumorigenesis.
When mutations speciﬁcally alter amino-acids in the DLG and ETGE
motifs of the Neh2 domain, the NRF2-KEAP complex is impaired, and
this leads to inhibition of the KEAP1-mediated degradation of NRF2
and constitutive expression of NRF2. This high transcriptional activity
of NRF2 occurs in lung, head/neck, esophageal, and skin cancers. In ad-
dition, recurrentNRF2mutation in advanced esophageal squamous can-
cer confers malignant potential and resistance to chemo/radiotherapy
[79–81]. Moreover, Shibata et al. reported that mutant NRF2 induces
proliferation, anchorage-independent growth, and tumorigenicity in
epithelial cells via the mammalian target of rapamycin pathway [82].
Furthermore, Hu et al. identiﬁed NRF2 mutations in cells from a patient
with non-small-cell lung cancer in which the mutations were located
within or near the DLG and ETGE motifs of the Neh2 domain. In addi-
tion, they found that all of these mutations were in the purine bases of
NRF2 [83].
Several investigations have shown that the loss of KEAP1 function
due to somatic mutations leads to constitutive and elevated activation
of NRF2–ARE-driven gene expression in cancer cells. Initially, a somatic
mutation was identiﬁed in the Kelch/DGR domain of KEAP1, where a
point-mutation of glycine to cysteine was found. This point-mutation
causes a conformational change that reduces its afﬁnity for NRF2, so
this loss-of-function of KEAP1 leads to the aberrant activation of NRF2
in cancer cells [84]. Furthermore, somatic mutations of KEAP1 in non-
small-cell lung cancer have been identiﬁed in highly-conserved
amino-acid residues in the Kelch or IVR domain. These mutations lead
to decreased KEAP1 function that causes increased accumulation, nucle-
ar translocation, and NRF2–ARE gene expression in lung cancer cells
[85]. Similarly, mutations in KEAP1 that lead to the constitutive activa-
tion of NRF2 have also been reported in breast, gallbladder, and endo-
metrial cancers, as well as the papillary adenocarcinoma form of lung
cancer [86–91].
Besides mutations of KEAP1, its epigenetic regulation is also consid-
ered to play a major role in the aberrant activation of NRF2. For the ﬁrst
time, Wang et al. demonstrated that epigenetic changes, such as hyper-
methylation of CpG sites in the KEAP1 promoter region, lead to down-
regulation of KEAP1 expression in human lung cancer cell lines and
tissues [92]. In addition, Muscarellaet al. showed that 47% hypermethy-
lation of the promoter region of the KEAP1 gene is present in the tissues
of non-small-cell lung cancer patients. Moreover, they predicted that
hypermethylation of KEAP1 is more frequent than KEAP1 gene muta-
tions in this cancer [93]. Epigenetic inactivation of the promoter region
of the KEAP1 gene has not only been identiﬁed in lung cancer but also in
prostate [77], malignant glioma [94], colorectal [95], and breast cancer
[96]. Collectively, these studies suggest that epigenetic changes in
KEAP1 lead to constitutive activation of theNRF2 pathway,which favors
the survival of tumors and drug resistance in cancer cells.
A new line of evidence suggests that single-nucleotide polymor-
phisms (SNPs) in NRF2 also play a critical role in lung cancer. Recently,
Suzuki et al. reported that an SNP in the humanNRF2upstreampromot-
er region (rs6721961) of minor A/A homozygotes affects the reduction
of NRF2 gene expression in lung cancer. As a result, the risk of lung can-
cer may be increased even in non-smokers [97]. Likewise, Okano et al.
identiﬁed SNP-homozygous (c.-617A/A) alleles in the NRF2 gene that
are associated with lung adenocarcinoma in non-smoking Japanese
women [98].
4. Inhibition of NRF2 by nuclear receptors
It is apparent that an additional regulatory mechanism independent
of KEAP1 exists for NRF2. The NRF2 signaling pathway can be regulated
by nuclear receptors, which are involved in various physiological
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ligand-dependent and/or -independent manner (Table 1).
Nuclear receptors are highly-conserved, and are involved in the
transduction of extracellular and intracellular signals [99]. Nuclear re-
ceptors selectively bind to small lipophilic/hydrophobic ligands that
provoke the transactivation of speciﬁc cis-regulatory DNA sequences
(gene-responsive elements) [100,101]. The binding of ligands to nuclear
receptors alters their conformation. As a result, nuclear receptors bind
with cofactors such as co-activators or co-repressors that are subse-
quently responsible for the upregulation or downregulation of their
downstream target genes. In contrast, the endogenous ligands of a sub-
set of nuclear receptors have yet to be identiﬁed. Those nuclear recep-
tors lacking deﬁned ligands are termed ‘orphan’ receptors [102]. In
humans, so far, 48 nuclear receptors have been identiﬁed, while mice
have 49 and rats 47 [103]. The nuclear receptor superfamily contains
seven subfamilies, NR1–NR6 and NR0 [104].
Most nuclear receptors are similar in their structural organization. In
general, they contain six conserved regions designated A to F (Fig. 4).
The N-terminal region contains two domains (A/B) termed activation
function 1 (AF1); these are the least-conserved domains, are highly var-
iable in length, and exhibit ligand-independent transactivation activity.
So far, no three-dimensional structure has been predicted for the A/B
domain [105]. Central region C has a DNA-binding domain (DBD)
which is said to be the most-conserved region. A pair of zinc ﬁngers in
domain C is critically responsible for DNA-speciﬁc contacts and interac-
tion. The ﬁrst zinc ﬁnger contains a shortmotif known as P-boxwhich is
responsible for direct DNA interaction and the speciﬁcity of DNA-
binding, and the second zinc ﬁnger contains a D-box which mediates
receptor dimerization. Domain D is less conserved among the nuclear
receptors; it acts as a ﬂexible hinge between two domains such as C
(DBD) and E (a ligand-binding domain). In addition, it contains the
nuclear localization signal that regulates the subcellular distribution of
nuclear receptors. The E region contains a ligand-binding domain
designated activation function 2 (AF2). AF2 has many functions includ-
ing interaction with lipophilic ligands, activation or repression of theFig. 3. Repression of NRF2 by nuclear receptors. Nuclear receptors such as RARα, RXRα, PPARγ,
that bind to either the RA response element or the PPAR-responsive element in various gene p
supports adipogenesis. ERα, ERRβ, and GR bind with their target DNA response elements in th
involved in cell growth, proliferation, and metabolism. The exact binding partners and functiontranscriptional activity of nuclear receptors, and dimerization with
other nuclear receptors. Finally, the C-terminal region (also known as
region-F or the F domain) is highly variable in sequence and little is
known about its function [106].4.1. Retinoids inhibit the NRF2 signaling pathway through retinoic acid
receptor alpha
The retinoids are natural and synthetic signalingmolecules structur-
ally related to vitamin A. Compounds such as retinol, retinal, retinoic
acid (RA), and retinyl esters belong to this group. Retinoids are potent
chemopreventive and tumor-suppressive agents because of their apo-
ptotic and anti-oxidant activity. A wide variety of studies in animal
models and clinical trials have shown the anticancer activity of RA
against lymphoma, leukemia, melanoma, lung cancer, cervical cancer,
kidney cancer, neuroblastoma, and glioblastoma [107].
Retinoids induce their physiological effects via interaction with
two distinct classes of nuclear receptors: retinoic acid receptors (RARs)
and retinoid X receptors (RXRs). These receptors are members of the
steroid/thyroid hormone receptor superfamily [108]. The RARs contain
three isotypes, RARα, RARβ, and RARγ, encoded by the RARA, RARB, and
RARG genes, and function as ligand-dependent transcription factors. There
are two important isoforms of RARα (α1 and α2) and RARγ (γ1 and γ2)
and ﬁve major isoforms of RARβ (β1, β2, β3, β4, and β1′). These isoforms
result from the differential use of promoters and alternative splicing [109].
RARs form heterodimers with their most common partners, RXRs.
Since RARs are ligand-dependent transcription factors, in the absence
of ligand an RAR/RXR heterodimer can interact with multiple co-
repressor proteins including the nuclear receptor co-repressor and
silencing mediator of retinoic acid and thyroid hormone receptor
(SMRT) that regulates the transcription of target genes. The RAR/RXR
heterodimer co-repressor proteins interact with complexes which have
histone deacetylase activity. Subsequently, the histone deacetylases pro-
voke the acetylation of histone tails and target gene expression [110].ERα, ERRβ, and GR inhibit Nrf2. RARα and RXRα, or PPARγ and RXRα, form heterodimers
romoters. RARα/RXRα is involved in cell differentiation and apoptosis. The PPARγ/RXRα
e promoters of target genes known as ERE, ERRE, and GRE respectively, which are mainly
s of ERRβ are unknown.
Table 1
List of nuclear receptors that inhibit the Nrf2–ARE pathway.
Nuclear
receptor
Ligand Mode of action Cell/tissue type Reference
PPARγ PGJ2 and TRO Directly binds with NRF2 and abrogates its transactivation Rat macrophages [121]
ERα 17β-estradiol Binds with NRF2 and inhibits its transactivation MCF-7 breast cancer cells, COS1 cells, Ishikawa cells [124–127]
RARα ATRA, AM580 Forms a protein complex with NRF2 and antagonizes its
transactivation
MCF-7 breast cancer cells, mouse small intestine [114]
RARγ ATRA Unknown MCF-7 breast cancer cells [114]
RXRα Not tested DBD of RXRα directly binds with Neh7 domain of Nrf2 and
block its transactivation
Human lung carcinoma-A549 cells, Caco2 cells, MCF-7
breast cancer cells, mouse liver
[27]
ERRβ Unknown Physically interacts with NRF2 and represses its transactivation COS-1 cells, Ishikawa cells [135]
GR 11β-HSD1, Dexamethasone SMRT binds to Neh4/Neh5 domains of NRF2 and mediates the
repression of NRF2 gene expression
H4IIE cells, HEK 293 cells, ARECS3 cells, HPCT-1E3 cells,
NIH 3T3 cells, rat liver tissue
[138,139]
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RXR heterodimer complex, leading to a reduction of the afﬁnity be-
tween the co-repressor and the complex. Subsequently, coactivator
proteins such as steroid receptor coactivators (SRC-1, SRC-2, and SRC-
3) and proteins that have histone acetyl transferase activity (such as
p300-CBP, P300/CBP-associated factor, and general control of amino-
acid synthesis protein 5-like 2) interact with high afﬁnity for the RAR/
RXR heterodimer which transactivates RA-targeted genes by binding
to downstream DNA response elements known as RA response ele-
ments [111]. For instance, the RAR/RXR heterodimer regulates cell
growth, differentiation, survival, and death while these nuclear recep-
tors are also implicated in cancer and metabolic diseases such as diabe-
tes and obesity [112,113].
Wang et al. [114] have shown that the induction of ARE-driven lucif-
erase activity is inhibited by all-trans retinoic acid (ATRA) in a stable
ARE-luciferase reporter cell line known as AREc32. In addition, ATRA re-
duces the luciferase activity of ARE genes such as aldo–keto reductase
family 1 member C1 (AKR1C1) and AKR1C2 at both themRNA and pro-
tein levels. Interestingly, ATRA does not affect the half-life of NRF2 or its
nuclear translocation and accumulation. Treatment of AREc32 cellswith
the potent NRF2-inducer tert-butylhydroquinone alone or along with
ATRA does not have any detectable effect on the blockade of NRF2 nu-
clear translocation and accumulation. Moreover, these workers found
that RARα speciﬁcally inhibits the luciferase activity of ARE-driven
gene expression. A subsequent study using RNAi knockdown strongly
supported the potent antagonistic role of RARα among the isoforms.
This study also revealed another isoform, RARγ, that has antagonistic
activity on NRF2. However RARγ is not as potent as RARα.
Most importantly, studies using both NRF2+/+and NRF2−/− mice
have shown that the expression of the ARE gene battery increases in
the small intestine of mice fed a vitamin A-deﬁcient diet, and this in-
crease is repressed by administration of ATRA. By contrast, in the
small intestine of NRF2-null mice, the expression of ARE-driven genesis
not affected by vitamin A. Altogether, the above ﬁndings suggest that
ATRA is an endogenous NRF2 inhibitor.Fig. 4. Common domain structure of nuclear receptors. Nuclear receptors contain six dom
transactivation. The C domain (also known as the DBD) is responsible for DNA binding. The pa
ization. Domain D acts as a hinge between domains C and E. The E domain is responsible for li4.2. Mechanism by which retinoid X receptor alpha inhibits NRF2
Similar to RARs, RXRs have three isotypes, RXRα, RXRβ, and RXRγ
encoded by the genes RXRΑ, RXRB, and RXRG. Each isotype has two
isoforms, RXRα1 and α2, RXRβ1 and β2, and RXRγ1 and γ2 [115]. The
human chromosomal localization of the RXR subtypes is as follows:
RXRα on chromosome 9 band q34.3, RXRβ on chromosome 6 band
21.3; and RXRγ on chromosome 1 band q22–q23 [116]. As discussed
earlier in this review, RXRs have a structure similar to other nuclear
receptors and mediate retinoid signaling by the formation of hetero-
dimers with RARs. In addition, RXRs can form heterodimers with
many other nuclear receptors such as those for thyroid hormone, vita-
min D, androgen, farnesoid X, and pregnane X, as well as peroxisome
proliferator-activated receptors (PPARs) and constitutive androstane
receptors [117]. Since RXRs form homo- and hetero-dimers with nucle-
ar receptors and are involved in the RA-induced signaling pathways,
based on their potency in different signaling pathways, synthetic RXR-
speciﬁc ligands (rexinoids) such as Bexarotene have been approved by
the Food and Drug Administration (USA) to treat cutaneous T-cell lym-
phoma and non-small cell lung cancer [118].
Although RXRs heterodimerize with other nuclear receptors, our
study speciﬁcally established that the heterodimerization of RXRα is
not required for NRF2 inhibition [27]. The primary result was that
RXRα inhibits both basal and inducible ARE-driven gene expression in
MCF7 cells and loss of RXRα increases the transactivation of NRF2-
dependent genes. Moreover, forced overexpression of RXRαmarkedly
reduces the mRNA levels of NRF2 target genes such as AKR1C1 and
heme oxygenase-1 at both the basal and inducible levels in Caco2 cells
in a ligand-independent fashion. Our further knockdown study and
GST pull-down assays together revealed that RXRα alone physically
binds with NRF2 in vitro. Interestingly, the RXRα-NRF2 interaction is
completely blocked at amino-acid residues 209–316 [a previously
unknown domain of NRF2-Neh7 (NRF2–ECH homology7)]. Moreover,
GST pull-down assays provided evidence that the RXRα140–205 region
that comprises the DBD of RXRα alone is sufﬁcient for interactionains, in which A and B constitute the AF-1 region, responsible for ligand-independent
ir of zinc ﬁngers known as P-box and D-box is responsible for DNA interaction and dimer-
gand binding, and the functions of the C-terminal domain (domain F) are unknown.
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revealed that RXRα physically binds with NRF2 and forms a heterodi-
meric protein–protein complex in the nucleus rather than the cytosol.
RXRα increases the sensitivity to anticancer drugs such as doxorubicin
in A549-RXRα cells. Finally, we hypothesized that binding of RXRα to
the Neh7 domain prevents the interaction of CBP with the transac-
tivation domains of NRF2 such as Neh4 and Neh5 because the Neh7 do-
main lies adjacent to the Neh5 domain and prevents the productive
interaction between the transactivation domains of NRF2 and the
basal transcription machinery (Fig. 5).
4.3. Antagonism of NRF2 by other nuclear receptors
4.3.1. PPARγ suppresses NRF2 activity
PPARs are nuclear receptors that belong to the thyroid hormone
receptor-like subfamily and serve as ligand-dependent transcrip-
tion factors [119]. They have three isoforms: PPARα, PPARβ, and
PPARγ. They heterodimerize with RXRs and regulate the transcription
of various genes by interacting with the PPAR-responsive element.
The major functions of PPARs include lipid and glucose homeostasis,
differentiation of adipocytes, and regulation of inﬂammation [120].
Thromboxane synthase (TXS) is a member of the cytochrome P450
superfamily of enzymes and plays a crucial role in cellular hemostasis.
For the ﬁrst time, Ikeda et al. reported transcriptional regulation of the
rat TXS gene by PPARγ in macrophages. During this study, they found
downregulation of TXS gene expression by PPARγ ligands such as 15-
deoxy-D12, 14-prostaglandin J2 and thiazolidinedione troglitazone. In
addition, overexpression of PPARγ suppresses TXS gene transcription.
Furthermore, they identiﬁed the element responsible for the PPARγ ef-
fect on the TXS gene, the NF-E2/AP-1 site, as well as reporting that
PPARγ directly interacts with NRF2 and represses its transactivation
[121].
4.3.2. Repression of NRF2 by estradiol (E2)-bound estrogen receptor alpha
(ERα)
The estrogen receptor is a ligand-dependent transcription factor in-
duced by the hormone estrogen. There are two estrogen receptor types,
ERα and ERβ. It iswell known that theDBDs of these receptors are ~97%
homologous [122]. These receptors bind with their respective estrogenFig. 5. Inhibition of NRF2 by the DBD of RXRα through the Neh7 domain. (A) In the ab-
sence of RXRα, NRF2 along with Maf protein is associated with the transcription machin-
ery that includes CBP and RNA polymerase II that lead to the activation of ARE genes.
(B) The DBD of RXRα interacts with the Neh7 domain of NRF2 that prevents binding of
the transcription elements CBP and RNA polymerase II and ultimately provokes the inhi-
bition of ARE gene expression.response elements and play a crucial role in different cancers including
prostate, breast, uterus, ovary, colon, lung, and stomach cancers, so they
are considered as drug targets in cancer therapy. ERα is speciﬁcally in-
volved in functions such as growth, proliferation, and glucose homeo-
stasis [123].
Ansell et al. ﬁrst demonstrated that E2 and other estrogens down-
regulate the activity of phase-II enzymes both in vitro and in vivo
[124]. In addition, they proposed that this downregulation increases
the oxidative DNA damage that results in the progression of cancer in
some estrogen-responsive tissues. Furthermore, another study by the
same group revealed that estrogens repress ARE-driven gene transcrip-
tion and enhance cancer progression in an NRF2-dependent manner,
and this is independent of Keap1-mediated degradation. Moreover, im-
munoprecipitation revealed a physical interaction between ERα and
NRF2 which is speciﬁcally dependent on ligands such as E2. In addition,
ERα represses NRF2-mediated transcription through either the A/B
(AF1) or the C domain [125].
Other studies have shown that inhibition of estrogen signaling leads
to activation of the NRF2 pathway in breast cancer. Yao et al. reported
that the ERα ligand-binding domain is required for the estrogen-
dependent inhibition of NQO1 promoter activity in breast cancer cells.
The results of ChIP assays have shown that estrogen recruits ERα and
a class-III histone deacetylase (SIRT1) at the NQO1 promoter, leading
to the inhibition of NQO1 transcription. In addition, anti-estrogen
shikonin-induced inhibition of ERα expression reverses the inhibitory
action of estrogen on NQO1 expression [126]. More recently, Lo et al.
also reported that E2-induced ERα represses activity of the NQO1 and
HMOX1 genes in an NRF2-dependent manner in MCF-7 breast cancer
cells [127].
4.3.3. ERRβ is a potent antagonist of NRF2
Estrogen-related receptors (ERRs) are members of the nuclear hor-
mone receptor family of steroid hormone receptors and contain three
isotypes, ERRα, ERRβ, and ERRγ, that were initially discovered as or-
phan receptors [128]. ERRs are thought to be closely related to estrogen
receptors and share similar target genes, co-regulatory proteins, and
sites of action [129]. Since ERRβ is an orphan receptor, little is known
about its function. However, a growing body of evidence suggests that
it plays a major role in early placental development [130], the prolifera-
tion of gonadal germ cells [131], the development and/or function of
endolymph-producing epithelia [132], tumor-suppression in prostate
cancer cells [133], and rod photoreceptor survival [134].
Zhou et al. showed that human ortholog of ERRβ-short-form hERRβ
(SFhERRβ) inhibits NRF2 transcriptional activity [135]. The results of
ARE-luciferase assays revealed that SFhERRβ inhibits the transcription-
al activity of HA-NRF2 (hemagglutinin-tagged NRF2), and increasing
the level of a SFhERRβ expression plasmid leads to the repression
of tertbutylhydroquinone-induced luciferase activity in COS-1 cells.
Moreover, this result established that SFhERRβ is a more potent inhibi-
tor of HA-NRF2 transactivation than other isoforms such as hERRα and
hERRγ. Furthermore, they have shown that overexpression of SFhERRβ
represses the endogenous NRF2-dependent ARE gene expression at
both the basal and inducible levels. Co-immunoprecipitation experi-
ments speciﬁcally revealed that SFhERRβ physically interacts with
NRF2 and represses its activity. Confocal immunoﬂuorescence micros-
copy established that SFhERRβ alters the subcellular localization of
NRF2. Additional analyses using SFhERRβ deletion mutants have
shown that SFhERRβ binds with NRF2 at multiple sites. Therefore, the
overall experimental data suggest that ERRβ exerts potent inhibitory
activity on NRF2-targeted gene expression.
4.3.4. Glucocorticoid receptor inhibits NRF2 activity
The glucocorticoid receptor (GR; also known as NR3C1) which
belongs to the nuclear receptor subfamily 3, is a ligand-induced tran-
scription factor, and is activated by the steroid hormones known as glu-
cocorticoids [136]. GRs regulate a number of genes through direct
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ments and play an important role in the regulation of a wide range of
physiological processes, such as immunity, intermediary metabolism,
skeletal growth, cardiovascular function, reproduction, and cognition
[137]. For the ﬁrst time, Ki et al. [138] investigated the repression of
NRF2-dependent GSTA2 gene activity by GRs. Dexamethasone (Dex),
a potent synthetic glucocorticoid that activates GRs, inhibits GSTA2 ex-
pression constitutively induced by oltipraz or t-BHQ inH4IIE cells. In ad-
dition, Dex-GR activation represses GSTA2 promoter-luciferase gene
activity but does not inhibit the nuclear translocation and oltipraz- or
t-BHQ-induced DNA activity of NRF2. Interestingly, deletion of the glu-
cocorticoid response element in the GSTA2 promoter suppresses the in-
hibitory activity of Dex. A series of experiments in their study revealed
that SMRT, a co-repressor of the steroid–GR complex, binds with the
Neh4/5 domain of NRF2 to mediate the repression of NRF2-dependent
gene expression. An additional small-interfering RNA study of SMRT
also clearly showed that it directly binds to the transactivation domains
of NRF2 (Neh4/Neh5). They hypothesized that the binding of SMRT,
recruited to the steroid–GR complex on the glucocorticoid response el-
ement, negatively regulates GSTA2 gene transcriptionwithNRF2 activa-
tion. These ﬁndings revealed that ligand-dependent GR activation may
lead to the repression of NRF2–ARE gene expression.
Recently, Kratschmar et al. showed that 11β-HSD1 (11β-hydroxy-
steroid dehydrogenase type 1) activates GRs through glucocorticoids
and leads to suppression of the NRF2-dependent antioxidant response.
Using transfected HEK-293 cells and hepatic H4IIE cells they found
that, when cells expressing 11β-HSD1 are treated with cortisone, the
marker genes NQO1, HMOX1, and GST2A are downregulated. At the
same time, a reversal effect on the suppression of NRF2-dependent
genes was found on treatment with 11β-HSD1 inhibitors. Furthermore,
they demonstrated that elevated glucocorticoids reduce the ability of
cells to detoxify H2O2 [139]. These observations clearly demonstrated
that 11β-HSD1-induced GR activation impairs the NRF2-dependent an-
tioxidant response.
5. Biological signiﬁcance of NRF2 regulation by nuclear receptors
Nuclear receptors are believed to control essential physiological
functions and are predominantly present in the nucleus, where they
bind with their respective DNA sequences (e.g. hormone-responsive el-
ements) and regulate gene expression [140]. Nuclear receptors have
been implicated in cancer, as well as metabolic and other diseases.
Hence, nuclear receptors are emerging as drug targets to treat these dis-
eases [105]. Likewise, NRF2 also plays an important role in cancer and
metabolic diseases. The regulation of nuclear receptors is mediated in
a ligand-dependent and a ligand-independent fashion. For instance,
ERα and RXRα physically interact with NRF2, form a protein–protein
complex, and negatively regulate ARE gene expression where ERα, but
not RXRα, requires the ligand estrogen. Conversely, downregulation of
nuclear receptors such as RXRα has been reported in several tumors, es-
pecially non-small cell lung cancer [141–143]. It is noteworthy that
most of the studies of aberrant NRF2 activation have been carried out
in non-small cell lung cancer cell lines. Similar toNRF2, somenuclear re-
ceptors play dual roles in the etiology of cancer. For example, loss of es-
trogen or its receptors contributes to the development or progression of
various tumors. On the other hand, overexpression of estrogen recep-
tors can lead to the development of different cancers, speciﬁcally breast
cancer. Hence, both activation and inhibition of estrogen receptors is re-
quired to modulate gene expression in different cancers [144]. Another
nuclear receptor, PPARγ, plays a dual role in cancers. It has been report-
ed that PPARγ acts as both a tumor inhibitor and a tumor promoter in
cancers of the colon, breast, urinary tract, and lung [145]. These ﬁndings
show that a distinct regulatory mechanism seems to exist between
NRF2 and nuclear receptors, and this is of considerable interest.
Indeed, it is interesting to note that several other receptors including
ERα [125,126], ERRβ [135], and PPARγ [121] repress NRF2. Repressionof NRF2 by nuclear receptors serves to limit the antioxidant capacity
of cells and inﬂuence their redox status. Itmay also inﬂuence themetab-
olism and disposition of xenobiotics. For example, loss of NRF2 activity
could diminish the oxidation and reduction reactions catalyzed by en-
zymes such as aldo–keto reductases and NQO1 in favor of those cata-
lyzed by other phase-I detoxiﬁcation enzymes, or it may decrease the
elimination of xenobiotics by transporters associated with multi-drug
resistance. It is possible that some of the enzymes or drug transporters
encoded by NRF2-target genes decrease the half-life of nuclear receptor
ligands or their disposition. It could therefore be envisaged that for nu-
clear receptor ligands to be efﬁcient, it might be advantageous to atten-
uate NRF2 activity.
Despite nuclear receptor-DNA interactions, an additional mecha-
nism that involves protein–protein interactions of nuclear receptor–
NRF2 could play an important role in hormone-related diseases. Most
of the ligands of nuclear receptors are hormones that play crucial roles
in numerous bodily functions. Recent evidence showed that NRF2 not
only has adverse effects in cancer but also in atherosclerosis [146]. In ad-
dition, theremay be as-yet unknown deleterious effects associatedwith
aberrant NRF2 activation in other diseases. Hence, the interplay be-
tween these two major signaling pathways allows ﬁne-tuning of the
regulation of essential biological processes. Thus, a better understand-
ing of the regulation of NRF2 by nuclear receptorsmay allow opportuni-
ties for the development of new treatments to inhibit constitutive
activation of the NRF2-ARE pathway.
6. Therapeutic perspective for inhibiting NRF2 through
nuclear receptors
So far, most research has focused on the activation of NRF2, but less
was known about its inhibition until the discovery of its oncogenic role.
However, the molecular mechanism involved in the role of NRF2 in
carcinogenesis still needs to be investigated. Meanwhile, in order to
overcome the NRF2-based drug resistance in cancer therapy, inhibition
of NRF2 is likely to become a new therapeutic approach. Recently, sev-
eral laboratories including ours have identiﬁed several NRF2 inhibitors
including endogenous proteins such as Bach1 [147], p53 [148], ATRA
[114], activating transcription factor 3 [149], E-cadherin [150], and
caveolin-1 [151] as well as nuclear receptors. In addition, exogenous in-
hibitors such as ochratoxin-A [152], luteolin [153], brusatol [154],
procyanidin [155], apigenin [156], chrysin [157], and trigonelline [158]
potently inhibit the NRF2 signaling pathway.
Coincidentally, a recent study has conﬁrmed the importance of the
Neh7 domain of NRF2 where caveolin-1 binds to the 281–289amino-
acid region and inhibits its transactivation [151]. Most nuclear receptors
are considered to be potential pharmacological targets for drug discov-
ery. Speciﬁc ligands or modulators have been shown to target nuclear
receptors for transcriptional regulation [159]. It is noteworthy that reg-
ulation of NRF2 is required in the nucleus rather than the cytosol be-
cause the transactivation of ARE genes is processed in the nucleus.
Thus, given the contribution of nuclear receptors to the inhibition of
NRF2, we conclude that targeting the Neh7 domain of NRF2 for its inhi-
bition by nuclear receptors may become a novel therapeutic approach
in cancer treatment.
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